AI tool aims to cut risky drug combos in seniors, but trial stalls
NCT ID NCT04710615
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested an artificial intelligence platform called Synapse to help doctors avoid dangerous drug interactions in older patients (65+). The goal was to see if the AI could reduce inappropriate prescriptions when patients left the hospital. However, the trial was terminated early, so we don't have enough data to know if it worked. The study involved 178 older adults in French hospitals.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Synapse platform (AI virtual assistant for medication review)
- What this could lead to
- If successful, this could help doctors prescribe safer medications for older adults by catching harmful drug interactions.
- What could go wrong
- The trial was terminated early, so we don't have clear results. It's unclear if the AI platform actually improves prescribing in real-world hospital settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRUG-DRUG INTERACTIONS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Bordeaux
Bordeaux, 33000, France
-
CHU de Bordeaux, Hôpital Pellegrin
Bordeaux, 33000, France
-
CHU de Bordeaux, Hôpital Xavier Arnozan
Pessac, 33400, France
-
CHU de Bordeaux, Hôpital Xavier Arnozan
Pessac, 33600, France
-
Centre Hospitalier de Libourne - Pôle Gériatrie
Libourne, 33500, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.